New York/London Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to cut US pricing last year under pressure from President Donald Trump.
Tougher negotiations could lead drugmakers to delay launches of new medicines in parts of Europe, potentially limiting patient access to them, several industry investors, a lobbyist and a pharmaceutical executive said.
Tensions over drug pricing in Europe are expected to be a major topic at the JP Morgan Healthcare Conference in San Francisco that starts on January 12, the premier annual event that pulls pharmaceutical executives and investors from around the world.
